News
CNSP
5.01
-8.91%
-0.49
CNS Pharmaceuticals GAAP EPS of -$0.37 misses by $0.13
Seeking Alpha · 1d ago
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Barchart · 1d ago
Weekly Report: what happened at CNSP last week (0803-0807)?
Weekly Report · 3d ago
Weekly Report: what happened at CNSP last week (0727-0731)?
Weekly Report · 08/03 10:15
Weekly Report: what happened at CNSP last week (0720-0724)?
Weekly Report · 07/27 10:19
Weekly Report: what happened at CNSP last week (0713-0717)?
Weekly Report · 07/20 10:15
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 07/14 12:05
Weekly Report: what happened at CNSP last week (0706-0710)?
Weekly Report · 07/13 10:17
Weekly Report: what happened at CNSP last week (0629-0703)?
Weekly Report · 07/06 10:21
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment
TipRanks · 07/02 11:58
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/01 12:05
Weekly Report: what happened at CNSP last week (0622-0626)?
Weekly Report · 06/29 10:16
Weekly Report: what happened at CNSP last week (0615-0619)?
Weekly Report · 06/22 10:25
Weekly Report: what happened at CNSP last week (0608-0612)?
Weekly Report · 06/15 10:26
Weekly Report: what happened at CNSP last week (0601-0605)?
Weekly Report · 06/08 10:21
Weekly Report: what happened at CNSP last week (0525-0529)?
Weekly Report · 06/01 10:26
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/26 12:06
Weekly Report: what happened at CNSP last week (0518-0522)?
Weekly Report · 05/25 10:30
Insider Boost: CNS Pharmaceuticals Director Quietly Ramps Up His Stake
TipRanks · 05/21 02:09
CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders
TipRanks · 05/19 21:01
More
Webull provides a variety of real-time CNSP stock news. You can receive the latest news about CNS Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.